Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants

Phase 1 Enrolling by invitation 40 enrolled Nanjing Chia-tai Tianqing Pharmaceutical

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a randomized, double-blind, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of NTB003 injection in healthy volunteers.

Timeline

Start: 2025-06-30
Primary completion: 2026-02-23
Completion: 2026-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NTB003	Unknown	—	—

Indications

No indication recorded.